Most people agree that Clinical Trials play an essential role in the discovery of new drugs. In the case of Parkinson's Disease the Michael J Fox Foundation each December produces a Webinar on "Research underway (in Clinical Trials) this year.
They display a bar graph that shows in a general way which "Phase" of Trial drugs are in (no start date, no real discussion of where they are in participant commitment level, no planned date of conclusion). There is NO indication of those drugs eliminated as ineffective (or having failed) during the year.
The end result is that PwP's (people with Parkinsons) get a sense that Clinical Trials are really a "big black hole" into which Drugs Showing Promise to Slow or Stop Progression of PD.... drop into, never to appear again. There seems to be no reluctance of research organizations to "announce" drugs that offer hope... and then there's ..... nothing. It's all VERY discouraging.
Below I have listed the drugs that fall into this category. This is just what I have uncovered in the last two years. I have absolutely no idea which have failed.... which have not gotten a sufficient number of participants. Which are being actively tested and which have been side-tracked . . . or worse yet abandoned.
Perhaps someone at the Michael J. Fox organization could compile some real answers to this for the people who suffer with Parkinson's.
AAV2-hAADC
Ambroxol
AZD3241
BIIB054
CDNF 18
Exenatide (Diabetes Drug)
Fucoidan
GM608
Inosine
Isradipine
LDN (Low Dose Naltrexone)
LRRK2
Mannitol
MSDC-0160 (Diabetes Treatment)
NAC
Neurturin
Nilotinib
Nicotine
NPT200-11
NRF2
Opicaone
OXB-102
PRX002
Ursodiol
Uridine
Vatiquinone
